These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 23252692)

  • 21. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.
    Schaeffer T
    J Med Toxicol; 2012 Dec; 8(4):400-7. PubMed ID: 23073726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The opioid crisis: a 21st century pain.
    Walker G
    Drugs Today (Barc); 2018 Apr; 54(4):283-286. PubMed ID: 29869649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
    Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
    J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The implications of tamper-resistant formulations for opioid rotation.
    Pappagallo M; Sokolowska M
    Postgrad Med; 2012 Sep; 124(5):101-9. PubMed ID: 23095430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges in the development of prescription opioid abuse-deterrent formulations.
    Katz NP; Adams EH; Chilcoat H; Colucci RD; Comer SD; Goliber P; Grudzinskas C; Jasinski D; Lande SD; Passik SD; Schnoll SH; Sellers E; Travers D; Weiss R
    Clin J Pain; 2007 Oct; 23(8):648-60. PubMed ID: 17885342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
    Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1321-33. PubMed ID: 26419615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
    Fanelli A; Sorella MC; Ghisi D
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abuse-deterrent formulations: part 1 - development of a formulation-based classification system.
    Mastropietro DJ; Omidian H
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):193-204. PubMed ID: 25374404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abuse of immediate-release opioids and current approaches to reduce misuse, abuse and diversion.
    Nalamachu SR; Shah B
    Postgrad Med; 2022 May; 134(4):388-394. PubMed ID: 30025214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combating an Epidemic of Prescription Opioid Abuse.
    Pon D; Awuah K; Curi D; Okyere E; Stern CS
    J Calif Dent Assoc; 2015 Nov; 43(11):673-8. PubMed ID: 26798885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain.
    Webster L; St Marie B; McCarberg B; Passik SD; Panchal SJ; Voth E
    J Opioid Manag; 2011; 7(3):235-45. PubMed ID: 21823554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.
    Stanos SP; Bruckenthal P; Barkin RL
    Mayo Clin Proc; 2012 Jul; 87(7):683-94. PubMed ID: 22766088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
    Salwan AJ; Hagemeier NE; Harirforoosh S
    Clin Drug Investig; 2018 Jul; 38(7):573-577. PubMed ID: 29651781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.
    Vadivelu N; Schermer E; Kodumudi G; Berger JM
    CNS Drugs; 2016 Jul; 30(7):637-46. PubMed ID: 27290716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders.
    Pergolizzi JV; Taylor R; LeQuang JA; Raffa RB
    Expert Opin Drug Deliv; 2018 Jun; 15(6):567-576. PubMed ID: 29739241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1.
    Kaye AD; Jones MR; Kaye AM; Ripoll JG; Galan V; Beakley BD; Calixto F; Bolden JL; Urman RD; Manchikanti L
    Pain Physician; 2017 Feb; 20(2S):S93-S109. PubMed ID: 28226333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current approaches in tamper-resistant and abuse-deterrent formulations.
    Mastropietro DJ; Omidian H
    Drug Dev Ind Pharm; 2013 May; 39(5):611-24. PubMed ID: 22537282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
    Park K; Otte A
    Annu Rev Biomed Eng; 2019 Jun; 21():61-84. PubMed ID: 30786212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?
    Raffa RB; Taylor R; Pergolizzi JV
    Expert Opin Drug Saf; 2014 Feb; 13(2):181-90. PubMed ID: 24206269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse- deterrent formulations.
    Pergolizzi JV; Raffa RB; Pergolizzi JS; Taylor R
    Curr Pharm Des; 2012; 18(37):6109-15. PubMed ID: 22747546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.